Celavet has beforehand collaborated with Dr. Watts to judge OK100 stem cells for remedy of equine tendon accidents

OXNARD, Calif.–(BUSINESS WIRE)–March 16, 2020–

Celavet Inc., a regenerative drugs firm creating stem cell-based therapies for the remedy and prevention of orthopedic accidents and ailments in giant and small animals, and a subsidiary of Celavie Biosciences, LLC, as we speak introduced Ashlee E. Watts, DVM, PhD, DACVS as principal investigator for a brand new equine tendinitis examine being submitted to the FDA’s Center for Veterinary Medicine (CVM).

Celavet Inc. Plans Submission of Equine Tendinitis Study to FDA’s Center for Veterinary Medicine and Announces Ashlee E. Watts, DVM, PhD, DACVS as Principal Investigator

Celavet is submitting the examine protocol to the CVM for Investigational New Animal Drug (INAD) standing. The tentative double-blind, randomized, placebo-controlled pivotal trial goals to check the protection and efficacy of Celavet’s undifferentiated allogeneic pluripotent equine (OK100) stem cells for the remedy of equine tendinitis.

Dr. Watts is Director of the Comparative Orthopedics and Regenerative Medicine Laboratory at Texas A&M University, in addition to Associate Professor of Equine Orthopedics and the Linda and Dennis H. Clark 68′ Chair of Equine Studies. Ashlee’s scientific and analysis expertise and specialised focus in regenerative drugs, osteoarthritis prevention and revolutionary methods to enhance musculoskeletal therapeutic lend energy to Celavet’s experience.

Previously, Dr. Watts was lead writer on an article describing a double-blind, placebo-controlled examine of Celavet’s OK100 stems cells in a big animal flexor tendonitis mannequin published in 2011 in Stem Cell Research & Therapy. Additionally, she was key investigator in a managed examine of Embryonic Stem Cells for the Treatment of Tendonitis involving OK100 stem cells at Cornell University in 2009 that demonstrated the flexibility of OK100 cells to revive tendon lesions to anatomical normality with no scar formation.

“We’re thrilled to have Dr. Watts as principal investigator for our study to test the safety and efficacy of OK100 stem cells for the treatment of equine tendinitis,” stated Sandy Solmon, CEO and President of Celavie Biosciences and Celavet. “We successfully worked with Dr. Watts previously to study our OK100 cells in equine tendon injuries and believe our collaboration is a crucial next step towards obtaining INAD approval from the CVM.”

Celavet builds upon the work of Celavie Biosciences to develop proprietary, pluripotent allogeneic stem cells for remedy of a variety of ailments and circumstances. To date, Celavet’s OK100 stem cells have been used to deal with over 400 horses with tendon and ligament accidents in multiple trials at greater than 35 veterinary facilities across the U.S. and signify the primary utility of undifferentiated stem cells in musculoskeletal veterinary accidents. In these trials, OK100 stem cells demonstrated potential to restore connective tissues in acute and persistent accidents in horses. No tumor formation, an infection or another lasting antagonistic occasions have been noticed.

About Celavie Biosciences

Celavie Biosciences is a privately-held firm whose mission is to enhance lives and restore hope by advancing regenerative stem cell therapies for the remedy of Parkinson’s illness and different issues of the central nervous system (CNS). The firm develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a powerful IP portfolio, together with 18 issued patents, and has an skilled administration group mixing experience in idea and cell know-how, product scalability and entrepreneurship. Celavet, a subsidiary, applies the identical proprietary applied sciences for the remedy and prevention of significant veterinary ailments. More data is obtainable at https://www.celavie.com/.

About Celavet

Celavet Inc., a subsidiary of Celavie Biosciences, LLC, is a regenerative drugs firm creating stem cell-based therapies for the remedy and prevention of orthopedic accidents and ailments in giant and small animals, with an goal to revive well being and mobility. Celavet makes use of the identical standardized and managed manufacturing strategies as utilized in human cell manufacture to determine equine, canine and feline stem cell traces. Stem cell traces from completely different species all categorical customary stem cell traits and can be found to deal with pathologies of their respective species. More data is obtainable at https://www.celavie.com/celavet/.

Celavet Inc. Plans Submission of Equine Tendinitis Study to FDA’s Center for Veterinary Medicine and Announces Ashlee E. Watts, DVM, PhD, DACVS as Principal Investigator

View supply model on businesswire.com: https://www.businesswire.com/news/home/20200316005444/en/

Hannah Mongeon
LaVoieHealthScience
(617)655-6765
[email protected]